Table 2:
Mutational Frequencies of Clones in Patients with Reported Summed VAFs of Greater Than 30%
| Patient | Number of Clones | Clonal Frequency (VAFs) | Reference |
|---|---|---|---|
| 1 | 5 |
PLCG2 L845fs (14.9%), PLCG2 R742P (6.1%), PLCG2 R665W (5.5%), PLCG2 S707P (5.3%), PLCG2 S707F (3.3%) |
[6] |
| 2 | 1 | PLCG2 R665W (45%) | |
| 3 | 1 | BTK C481F (84%) | |
| 4 | 4 |
PLCG2 L845F (23.8%), BTK C481S (6.8%), PLCG2 S707Y (6.6%), PLCG2 R665W (2%) |
|
| 5 | 1 | BTK C481S (37.8%) | |
| 6 | 1 | BTK C481S (47.5%) | |
| 7 | 1 | BTK C481S (74.7%) | |
| 8 | 1 | BTK C481S (56.5%) ( | [5] |
| 9 | 2 | BTK C481S (71%), BTK C481R (18.1%) | |
| 10 | 1 | BTK C481S (53%) | |
| 11 | 2 | BTK C481A (45.3%), BTK C481S (42.5%) | |
| 12 | 1 | BTK C481S (94.8%) | |
| 13 | 1 | BTK C481S (34.9%) | |
| 14 | 2 | BTK C481S (26.9%), PLCG2 (13.2%) | |
| 15 | 1 | BTK C481S (45.8%)1 | |
| 16 | 1 | BTK C481S (52%)1 | |
| 17 | 1 | BTK C481S (83.4%) | |
| 18 | 1 | BTK C481S (52.4%) | |
| 19 | 1 | PLCG2 R665W (35.1%) | |
| 20 | 2 | PLCG2 (D993Y), BTK C481F (8.5%) | |
| 21 | 1 | BTK C481F (100%) | |
| 22 | 1 | BTK C481S (80%) | |
| 23 | 1 | BTK C481S (38.8%) | |
| 24 | 1 | BTK C481S (85.6%) | |
| 25 | 4 |
BTK C481S (78.2%), PLCG2 L845F (4.7%), PLCG2 R665W (0.26%), PLCG2 S707Y (0.17%) |
[10] |
| 26 | 5 |
PLCG2 L845F (18.3%), BTK C481R (15.8%), BTK C481S (8.8%),2 PLCG2 R665W (7.3%), BTK C481S (7.2%)2 |
|
| 27 | 1 | BTK C481S (57.3%) | |
| 28 | 2 |
BTK C481S (32.6%) PLCG2 6nt deletion (below limit of detection) |
|
| 29 | 3 |
BTK C481S (90.7%),2
BTK C481S (8.5%),2
BTK C481R (2.5%) |
[11] |
1
Denotes samples that were CD19+ selected prior to sequencing.
2
Sequencing indicates that different nucleotides were used to encode for the same mutated amino acid; thus, more than one clone with the reported amino acid change was present.